Abstract

BackgroundIdentifying lncRNA-disease associations not only helps to better comprehend the underlying mechanisms of various human diseases at the lncRNA level but also speeds up the identification of potential biomarkers for disease diagnoses, treatments, prognoses, and drug response predictions. However, as the amount of archived biological data continues to grow, it has become increasingly difficult to detect potential human lncRNA-disease associations from these enormous biological datasets using traditional biological experimental methods. Consequently, developing new and effective computational methods to predict potential human lncRNA diseases is essential.ResultsUsing a combination of incremental principal component analysis (IPCA) and random forest (RF) algorithms and by integrating multiple similarity matrices, we propose a new algorithm (IPCARF) based on integrated machine learning technology for predicting lncRNA-disease associations. First, we used two different models to compute a semantic similarity matrix of diseases from a directed acyclic graph of diseases. Second, a characteristic vector for each lncRNA-disease pair is obtained by integrating disease similarity, lncRNA similarity, and Gaussian nuclear similarity. Then, the best feature subspace is obtained by applying IPCA to decrease the dimension of the original feature set. Finally, we train an RF model to predict potential lncRNA-disease associations. The experimental results show that the IPCARF algorithm effectively improves the AUC metric when predicting potential lncRNA-disease associations. Before the parameter optimization procedure, the AUC value predicted by the IPCARF algorithm under 10-fold cross-validation reached 0.8529; after selecting the optimal parameters using the grid search algorithm, the predicted AUC of the IPCARF algorithm reached 0.8611.ConclusionsWe compared IPCARF with the existing LRLSLDA, LRLSLDA-LNCSIM, TPGLDA, NPCMF, and ncPred prediction methods, which have shown excellent performance in predicting lncRNA-disease associations. The compared results of 10-fold cross-validation procedures show that the predictions of the IPCARF method are better than those of the other compared methods.

Highlights

  • Identifying Long non-coding RNA (lncRNA)-disease associations helps to better com‐ prehend the underlying mechanisms of various human diseases at the long noncoding RNAs (ncRNAs) (lncRNAs) level and speeds up the identification of potential biomarkers for disease diagnoses, treatments, prognoses, and drug response predictions

  • We develop a new automated method for predicting lncRNA-disease associations based on incremental principal component analysis (IPCA) and random forest (RF) technology, which we named IPCARF

  • Biological experiments have continuously been the primary means of identifying lncRNA-disease associations

Read more

Summary

Introduction

Identifying lncRNA-disease associations helps to better com‐ prehend the underlying mechanisms of various human diseases at the lncRNA level and speeds up the identification of potential biomarkers for disease diagnoses, treatments, prognoses, and drug response predictions. As the amount of archived biological data continues to grow, it has become increasingly difficult to detect potential human lncRNA-disease associations from these enormous biological datasets using traditional biological experimental methods. Develop‐ ing new and effective computational methods to predict potential human lncRNA diseases is essential. Bioinformatics has received increasing attention from both the public and the scientific community as biomedicine and sequencing technology developed. Regions of the human genome that do not encode protein sequences are usually transcribed as noncoding RNAs (ncRNAs) [1]. The difference is that lncRNAs are more than 200 nucleotides in length [2], and they comprise the vast majority of noncoding RNAs. In recent years, lncRNAs have attracted wide attention from researchers. Increasing evidence indicates that lncRNAs usually play carcinogenic or tumour suppressor roles in human cancers [3, 4], including prostate cancer [5], hepatocellular carcinoma (HCC) [6] , colon cancer [7] , lung cancer [8], bladder cancer [9], and others

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call